The wallstent in native coronary arteries (WIN) multicenter randomized trial: in hospital acute results

Bilodeau, Luc; Schreiber, Theodore; Hilton, John; Rosenblum, S.; Mehta, Suneela; McIvor, Michael; Krajcer, Z; Wilson, Bivin; Senerchia, Cynthia; Beck, Laura; Pedan, A

doi:10.1016/s0735-1097(98)80995-9

Cited by 4 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the comparison of DES and BMS for single-vessel disease does not involve any question of mortality and therefore can easily be represented in a much simpler way. [52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69]70+ CIC In this section we introduce a simplified model for this purpose, which can be presented on a single Excel worksheet and encapsulates virtually all the detail of the original LRIG model for comparison of stents.…”

Section: Economic Modelling: Simplified Model For Non-drug Eluting Vementioning

confidence: 99%

Coronary artery stents: a rapid systematic review and economic evaluation

Hill¹,

Bagust²,

Bakhai³

et al. 2004

Health Technol Assess

144

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

Section: Economic Modelling: Simplified Model For Non-drug Eluting Vementioning

confidence: 99%

Coronary artery stents: a rapid systematic review and economic evaluation

Hill¹,

Bagust²,

Bakhai³

et al. 2004

Health Technol Assess

144

View full text Add to dashboard Cite

show abstract

“…Due to the given rate of restenosis the EPHESOS stent can be considered as a safe and effective stent types (10, [14][15][16]. This rate shows that EPHESOS has an advantage over different types of stents (7,10,17,18). A low rate of restenosis can somewhat be explained by a large mean RVD of the sample.…”

Section: Discussionmentioning

confidence: 99%

In-hospital, six - and eighteen month's results of Ephesos coronary stent implantation in patients with unstable or stable angina

Pershukov¹,

Batyraliev

Самко³

et al. 2004

ELECTRON J GEN MED

View full text Add to dashboard Cite

This is an open non-randomized study designed to evaluate clinical and angiographic shortand long-term results of the EPHESOS stent implantation in 457 patients (M/F=348/109) with unstable angina (UA) or stable angina (SA) and native lesions. In SA group 268 stents were implanted in 231 patients. In UA group 271 stents were implanted in 226 patients. 46% of lesions were complex. The length of stenosis was 12.9±6.7 mm in SA group, and 14.1±7.4 mm in UA group. The rate of long stenosis was 30%. Coronary Stenting success rate appeared to be 99% of cases free from acute thrombosis. 1.3% of patients in UA group suffered a non-fatal myocardial infarction (MI) during the in-hospital period. Major adverse cardiac events (MACE) rate including mortality rate and the occurrence of recurrent angina, MI and restenosis as well as repeat revascularization during 6-month follow-up, was 15.6% in SA group and 18.1% in UA group. Angiographic 6-month control revealed the loss index of 0.22±0.20 in SA group and 0.30±0.27 in UA group.18-month follow-up did not reveal any significant differences in MACE rate between the groups (21.6% for SA and 22.6% for UA group). These results indicate the efficacy and safety of EPHESOS stent with reasonable rates of stent thrombosis and restenosis in SA and UA patients undergone high risk endovascular interventions.

show abstract

“…It is also flexible, easily trackable, completely repositionable if needed, and fully removable since it is sheath protected [12]. Furthermore, its successful use in complex and long dissections has been described [12,13]. The mechanism by which coronary perforation was successfully treated by the Magic Wallstent is probably related to the intima impaction into the media, consequently forming a clot that stops transmural hemorrhage.…”

Section: Discussionmentioning

confidence: 99%